Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Investors sued Novo Nordisk over misleading growth claims, causing a 21.8% stock drop after sales outlook was cut.

flag A class action lawsuit has been filed against Novo Nordisk A/S (NVO) on behalf of investors who bought its stock between May 7 and July 28, 2025, alleging the company made misleading statements about its growth prospects for Wegovy and Ozempic amid competition and compounded GLP-1 use. flag The complaint claims Novo Nordisk downplayed risks from a personalization exception in compounding rules and overestimated patient shifts to its branded drugs. flag After the company lowered its 2025 sales outlook on July 29, 2025, citing slower growth, increased competition, and persistent compounded use, its stock dropped 21.83% in one day. flag Investors who suffered losses during the class period may qualify to join the case by September 30, 2025, with firms like Pomerantz LLP, Levi & Korsinsky LLP, and The Law Offices of Frank R. Cruz handling the litigation. flag Participation is voluntary and without cost.

32 Articles